Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60318
Name acute promyelocytic leukemia
Definition An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia acute promyelocytic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 D835Y Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin acute promyelocytic leukemia predicted - sensitive detail...
FLT3 D835Y Tretinoin acute promyelocytic leukemia predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01409161 Phase II Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Recruiting USA 0
NCT01869803 Phase I Gemtuzumab ozogamicin Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia Approved for marketing USA 0
NCT02339740 Phase III Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Active, not recruiting USA | CAN 4
NCT02688140 Phase III Arsenic trioxide + Idarubicin + Tretinoin Mercaptopurine + Methotrexate + Tretinoin Cytarabine + Idarubicin + Tretinoin Mitoxantrone + Tretinoin Idarubicin + Tretinoin Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Active, not recruiting ITA | FRA | ESP | DEU 1
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT04793919 Phase II Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin Arsenic trioxide + Tretinoin Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Recruiting ITA | FRA | ESP | DEU | BEL 7
NCT04996030 Phase I Arsenic trioxide + SY-2101 SY-2101 Arsenic trioxide A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia Recruiting USA 0